Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta™, Flexion's lead drug candidate (also known as FX006) Zilretta received Fast-Track designation by U.S. Food & Drug Administration (FDA) in 2015; planned NDA submission on track for second half
NDA for Zilretta TM (FX006) filed in December 2016 and accepted by FDA in February 2017 PDUFA action date set for October 6, 2017 Commercialization plans on target for potential Q4 launch of Zilretta Frederick Driscoll, Chief Financial Officer, to retire effective March 31, 2017 Conference
BURLINGTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that three new executives have joined the company in key marketing, medical affairs and market access roles. Mark Fraga, Scott Kelley, MD, and Dan Thornton take on vice president positions
Flexion’s new locally delivered product candidate, FX301, will combine Xenon’s NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel FX301 is a potential first-in-class therapy with the aim of providing pain relief via peripheral nerve block for up to a week following surgery while
Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a year New preclinical program holds potential to be a next-generation therapeutic that could provide
